The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 25, 2019

Filed:

Oct. 24, 2013
Applicants:

Tokyo University of Agriculture and Technology, Tokyo, JP;

Japan Innovative Therapeutics, Inc., Nagoya-shi, Aichi, JP;

Inventors:

Hiroshi Matsuda, Tokyo, JP;

Akane Tanaka, Tokyo, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/573 (2006.01); G01N 33/53 (2006.01); C12Q 1/25 (2006.01); G01N 33/50 (2006.01); A61K 45/00 (2006.01); A61K 31/352 (2006.01); G01N 33/68 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01); A61K 31/245 (2006.01); A61K 47/10 (2017.01); C07K 16/40 (2006.01);
U.S. Cl.
CPC ...
G01N 33/5044 (2013.01); A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 31/245 (2013.01); A61K 31/352 (2013.01); A61K 45/00 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); C07K 16/40 (2013.01); G01N 33/5023 (2013.01); G01N 33/5047 (2013.01); G01N 33/573 (2013.01); G01N 33/6893 (2013.01); G01N 2333/96441 (2013.01); G01N 2800/164 (2013.01);
Abstract

Provided are a therapeutic or prophylactic agent for retinopathy of prematurity (ROP) that is suited to the pathogenic mechanism of ROP and a method of testing for ROP. The therapeutic or prophylactic agent for ROP uses at least one substance from the group consisting of inhibitors against tryptase derived from mast cells and/or mast cell stabilizers as an active ingredient. The testing method for ROP includes detecting a marker substance that can be released by degranulation of mast cells in a biological sample originating from a patient and determining the presence or absence of ROP on the basis of the detected amount of the marker.


Find Patent Forward Citations

Loading…